- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- PR positive
- ER negative
- PR negative
- KRAS positive
- EGFR negative
- PD-L1 negative
- BRAF positive
- p16 positive
- ALK negative
- HLA-A positive
- IDH positive
- ALK positive
- BRCA1 positive
- BRCA2 positive
- CD20 positive
- MET positive
- CD19 positive
- HLA positive
- ROS1 positive
- IDH negative
- TP53 positive
- MSI-H positive
- ROS1 negative
- p16 negative
- MYC positive
- HLA negative
- NRAS positive
- PALB2 positive
- dMMR positive
- BRAF negative
- HPV positive
- HR positive
- RET positive
- FLT3 positive
- RB1 negative
- HLA-A negative
- RB1 positive
- BRCA positive
- NF1 positive
- NTRK positive
- PIK3CA positive
- CD22 positive
- HPV negative
- MET negative
- ATM positive
- BCL2 positive
- MGMT negative
- RAS positive
- MMR positive
- ARID1A positive
- BCL6 positive
- CD30 positive
- KIT positive
- KRAS negative
- anti-dsDNA positive
- ANA positive
- CCND1 positive
- HRAS positive
- MGMT positive
- MLH1 positive
- MSH6 positive
- RAD51 positive
- BCR-ABL1 positive
- BRIP1 positive
- CHEK2 positive
- HbSS positive
- MSH2 positive
- PD-1 positive
- PMS2 positive
- Philadelphia chromosome positive
- RAS negative
- CFTR positive
- KMT2A positive
- NPM1 positive
- NTRK1 positive
- PTEN positive
- RET negative
- ASXL1 positive
- CD123 positive
- HBV DNA positive
- MMR negative
- MSI negative
- MSI positive
- MSS positive
- ctDNA positive
- AR positive
- FANCA positive
- HBV DNA negative
- HBsAg positive
- MSI-H negative
- MSS negative
- NRAS negative
- PD-1 negative
- RUNX1 positive
- TP53 negative
- p53 positive
- BCR-ABL positive
- CD33 positive
- CDK4 positive
- FGFR2 positive
- HBsAg negative
- HR negative
- NF2 positive
- NTRK negative
- RAD51C positive
- anti-Sm positive
- dMMR negative
- t(11;14) positive
- ABCA4 positive
- BAP1 positive
- BARD1 positive
- BRCA negative
- BRCA1 negative
- BRCA2 negative
- CCNE1 positive
- CD3 positive
- CDK12 positive
- DLL3 positive
- Del(17p) positive
- FGFR positive
- FGFR3 positive
- GATA2 positive
- GRN positive
- HPV16 positive
- Ki-67 positive
- MECP2 positive
- MTAP positive
- PDGFRA positive
- Ph positive
- RAD51D positive
- RAD54L positive
- RAF positive
- RF positive
- SMN1 positive
- STK11 positive
- T790M positive
- TERT positive
- TROP2 positive
- ZnT8 positive
- t(14;16) positive
- AKT1 positive
- APOL1 positive
- CD19 negative
- CD4 positive
- CD70 positive
- CDK6 positive
- CHEK1 positive
- CLDN18.2 positive
- COL7A1 positive
- DMD positive
- DMPK positive
- DNMT3A positive
- EPCAM positive
- EZH2 positive
- FANCL positive
- FLT3 negative
- FMR1 positive
- FRα positive
- GPC3 positive
- HBB positive
- HBcAb negative
- HbSC positive
- HbSβ0-thalassemia positive
- IA-2 positive
- JAK2 positive
- MDM2 positive
- MLH1 negative
- MSH2 negative
- MSH6 negative
- NBN positive
- NF1 negative
- PMS2 negative
- SF3B1 positive
- TROP2 negative
- U2AF1 positive
- complex karyotype positive
- t(14;20) positive
- t(4;14) positive
- t(9;22) positive
- AChR positive
- AKT negative
- APC positive
- APOE ε4 positive
- ATR positive
- C5 positive
- CA-125 positive
- CCND2 positive
- CCND3 positive
- CD30 negative
- CD4 count positive
- CD5 positive
- CD8 positive
- CTNNB1 positive
- EBV positive
- Ex19del positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Allogeneic Hematopoietic Cell Transplantation
- Alopecia from Prior Anti-Cancer Therapy
- Alopecia from Prior Treatment
- Anemia from Prior Anti-Cancer Therapy
- Anti-EGFR Therapy (Cetuximab or Panitumumab)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
8899 trials
Columbus, OH (<10 mi)
Recruiting
Phase 2 & 3
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing an injectable medication called efgartigimod PH20 SC in people with certain muscle inflammation diseases. The goal is to see if it helps improve their condition by lowering harmful proteins in their blood. The study focuses on patients with specific subtypes of these diseases who often don't respond well to usual treatments. Efgartigimod was developed for autoimmune diseases and has been approved for treating a specific muscle condition in adults.
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares a new treatment, frexalimab, with an existing pill, teriflunomide, in adults aged 18-55 who have relapsing multiple sclerosis. The study aims to see if frexalimab can reduce the frequency of symptom relapses better than teriflunomide. Participants will be monitored over several years.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA-335140 to see if it helps people with major depressive disorder. It includes participants who have no safety concerns. The medication aims to improve mood by affecting brain chemicals.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new medication called NMRA 335140 to see if it can help people with Major Depressive Disorder feel less depressed. The study involves an initial evaluation and a treatment phase where participants will receive either the medication or an inactive substance. The medication likely works by changing brain chemicals that affect mood.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a drug to see if it's safe and effective to treat a lung disease called Idiopathic Pulmonary Fibrosis.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studied if digital therapies plus standard care can reduce symptoms of schizophrenia in teens & adults.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Graves Disease trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests batoclimab, a medication given as weekly injections under the skin, to see if it can help reduce eye bulging in patients with proptosis. The treatment starts with a higher dose for a few months, followed by a lower dose for a few more months. Batoclimab works by adjusting the immune system to decrease inflammation and swelling around the eyes.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a vaccine to protect older adults from serious E. coli infections. The vaccine trains the immune system to recognize and fight off nine types of harmful E. coli bacteria. In earlier studies, a similar vaccine caused fever and/or diarrhea in some participants and provided limited protection against illness.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug, lanifibranor, to see if it can treat adults with a fatty liver disease called NASH, and who also have liver fibrosis stage 2 or 3.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if a new drug, BHV-3000, is safe and effective in treating migraines in children and adolescents.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if lebrikizumab is effective and safe for adults with chronic sinus and nasal polyps who are already using nasal corticosteroids. The study will take around
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with a specific liver condition called non-cirrhotic NASH/MASH. The patients have significant liver damage but not cirrhosis. EFX aims to improve liver health by reducing swelling and scarring in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called efruxifermin (EFX) to see if it can help people with specific liver conditions. These conditions are hard to treat with current methods. EFX aims to improve liver health by reducing inflammation and fat buildup in the liver.
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 43 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Drug Has Already Been Approved
Get notified when new Gastroparesis trials are postedWe'll send you an email whenever new trials are posted
SummaryThis trial seeks to evaluate if CIN-102 can reduce symptoms of diabetic gastroparesis in adults. Participants will compare effects of drug and placebo treatments over 12 weeks.
Columbus, OH (<10 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
1
2
3
…50